ExoZymes (EXOZ) CSO Tyler Korman Receives 32,964 Shares (RSU Vest)

What Happened Tyler Korman, Chief Scientific Officer of ExoZymes (EXOZ), had 32,964 restricted stock units (RSUs vest) convert into 32,964 shares of common stock on August 19, 2026. The filing shows an acquisition entry for 32,964 shares (conversion of derivative security) and a corresponding disposition entry reported at $0 (both coded as derivative transactions). No cash proceeds or per-share cash price are reported for these entries.

Key Details

• Transaction date: August 19, 2026; Form 4 filed August 25, 2026 (filed late relative to the standard 2‑business‑day rule).
• Reported amounts: 32,964 shares acquired via conversion; a matching 32,964-share disposition reported at $0 (derivative).
• Price/value: Acquisition price not applicable (conversion); disposition recorded at $0 — filing does not show cash proceeds.
• Shares owned after the transaction: Not specified in the filing.
• Footnotes: RSUs convert on a one‑for‑one basis. The reporting person was granted an aggregate 79,104 RSUs on Mar 28, 2022 and May 1, 2023, vesting periodically; the first vesting on Aug 19, 2026 was for 32,964 shares.
• Timeliness: Transaction reported on Form 4 six days after the transaction date; marked late relative to normal deadlines (transactionTimeliness = 'L').

Context This was a routine compensation event (RSU vest/convert), not an open‑market purchase or sale that would signal a new personal investment. The filing’s disposition at $0 is reported as a derivative entry; the form does not state that shares were sold for cash. Retail investors should treat RSU vesting as a standard insider compensation occurrence rather than an explicit buy/sell signal.